ArticleTexas Heart Institute journal2017
Serum MicroRNA-27b as a Screening Biomarker for Left Ventricular Hypertrophy.
Article in Texas Heart Institute journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- A meta-analysis of the diagnostic value of microRNA for hypertensive left ventricular hypertrophy.Frontiers in cardiovascular medicine · 2022Pooled it
- SOX2-OT serves as a diagnostic and prognostic biomarker for hypertensive left ventricular hypertrophy by targeting miR-30d-5p.Molecular and cellular biochemistry · 2026Article
- MicroRNAs in Pediatric Primary Hypertension: Promising Biomarkers or Context-Dependent Regulators?-A Narrative Review.Biomolecules · 2026Review
- Circulating miR-16 as an Early Biomarker of Subclinical Myocardial Strain Impairment in Pediatric Primary Hypertension.International journal of molecular sciences · 2026Article
- ATHENA Study - The Role of Circulating Plasma MicroRNAs in Paediatric Patients with Untreated Primary Hypertension: Baseline Expression and Exercise-Induced Changes.Kidney & blood pressure research · 2026Observational
- MiR-107 as a Biomarker Predicts Cardiac Hypertrophy in Chronic Hemodialysis Patients.Anatolian journal of cardiology · 2025Article
- Anticoagulation Therapies and microRNAs in Heart Failure.Biomolecules · 2025Review
- MicroRNA-133a and MicroRNA-145 May Be Involved in the Development of Hypertension-Mediated Organ Damage in Children with Primary Hypertension-A Preliminary Study.Journal of clinical medicine · 2024Article
- Peripheral blood mononuclear cells expression of miR-200c, miR-125b, miR-27b, miR-203, and miR-155 in patients with significant or insignificant coronary artery stenosis.Scientific reports · 2023Article
- Non-coding RNAs regulating mitochondrial function in cardiovascular diseases.Journal of molecular medicine (Berlin, Germany) · 2023Review
- Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy.ESC heart failure · 2023Article
- MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling.Cardiovascular research · 2022Article
- Relationship Between Circulating MicroRNAs and Left Ventricular Hypertrophy in Hypertensive Patients.Frontiers in cardiovascular medicine · 2022Article
- Effect of miR-27b-5p on apoptosis of human vascular endothelial cells induced by simulated microgravity.Apoptosis : an international journal on programmed cell death · 2020Article
- Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease.Frontiers in physiology · 2020Review
- Article
- Plasma protein thiolation index (PTI) as a potential biomarker for left ventricular hypertrophy in humans.PloS one · 2019Article
- Circulating miR-27b as a Biomarker of the Development and Progression of Carotid Artery Stenosis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-27b (miR-27b) is frequently upregulated in pressure-overloaded hypertrophic hearts. The clinical implications of aberrant circulating miR-27b in the diagnosis and management of left ventricular hypertrophy warrant study. We investigated whether serum miR-27b is a biomarker for left ventricular hypertrophy (LVH). We used stem-loop reverse-transcription quantitative polymerase chain reaction techniques to analyze serum miR-27b levels in 200 hypertensive patients with LVH, 100 hypertensive patients without LVH, and 100 healthy volunteers. We found that serum miR-27b levels were significantly higher in the hypertensive patients with LVH than in the hypertensive patients without LVH and in the healthy volunteers. Upon receiver operating characteristic curve analysis, serum miR-27b had an area under the curve of 0.885 with 91% sensitivity and 73% specificity in distinguishing hypertensive patients with LVH from healthy volunteers (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.